Evidence-based decision-making for vaccine introductions: Overview of the ProVac International Working Group's experience.

Abstract:

INTRODUCTION:Pan American Health Organization's (PAHO) ProVac Initiative aims to strengthen countries' technical capacity to make evidence-based immunization policy. With financial support from the Bill and Melinda Gates Foundation, PAHO established the ProVac International Working Group (IWG), a platform created for two years to transfer the ProVac Initiative's tools and methods to support decisions in non-PAHO regions. METHODS:In 2011, WHO Regional Offices and partner agencies established the IWG to transfer the ProVac framework for new vaccine decision support, including tools and trainings to other regions of the world. During the two year period, PAHO served as the coordinating secretariat and partner agencies played implementing or advisory roles. RESULTS:Fifty nine national professionals from 17 countries received training on the use of economic evaluations to aid vaccine policy making through regional workshops. The IWG provided direct technical support to nine countries to develop cost-effectiveness analyses to inform decisions. All nine countries introduced the new vaccine evaluated or their NITAGs have made a recommendation to the Ministry of Health to introduce the new vaccine. DISCUSSION:Developing countries around the world are increasingly interested in weighing the potential health impact due to new vaccine introduction against the investments required. During the two years, the ProVac approach proved valuable and timely to aid the national decision making processes, even despite the different challenges and idiosyncrasies encountered in each region. The results of this work suggest that: (1) there is great need and demand for technical support and for capacity building around economic evaluations; and (2) the ProVac method of supporting country-owned analyses is as effective in other regions as it has been in the PAHO region. CONCLUSION:Decision support for new vaccine introduction in low- and middle-income countries is critical to guiding the efficient use of resources and prioritizing high impact vaccination programs.

journal_name

Vaccine

journal_title

Vaccine

authors

Jauregui B,Garcia AG,Bess Janusz C,Blau J,Munier A,Atherly D,Mvundura M,Hajjeh R,Lopman B,Clark AD,Baxter L,Hutubessy R,de Quadros C,Andrus JK

doi

10.1016/j.vaccine.2014.10.090

subject

Has Abstract

pub_date

2015-05-07 00:00:00

pages

A28-33

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(15)00020-1

journal_volume

33 Suppl 1

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Comparative evaluation of ELPylated virus-like particle vaccine with two commercial PCV2 vaccines by experimental challenge.

    abstract::Porcine circovirus type 2 (PCV2) is an economically important swine pathogen and vaccination is the primary tool for the disease control. Previously, we developed a more cost-effective PCV2 virus-like particle (VLP) vaccine by using ELPylation technology. In the present study, we compared the ELPylated VLP (ELP-VLP) P...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.03.060

    authors: Li Y,Lin Y,Xin G,Zhou X,Lu H,Zhang X,Xia X,Sun H

    更新日期:2020-05-13 00:00:00

  • What is the responsibility of national government with respect to vaccination?

    abstract::Given the ethical aspects of vaccination policies and current threats to public trust in vaccination, it is important that governments follow clear criteria for including new vaccines in a national programme. The Health Council of the Netherlands developed such a framework of criteria in 2007, and has been using this ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.10.008

    authors: Verweij MF,Houweling H

    更新日期:2014-12-12 00:00:00

  • Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines.

    abstract::Although an effective killed virus vaccine to prevent illness due to Japanese encephalitis virus (JEV) infection exists, many authorities recognize that a safe, effective live JEV vaccine is desirable in order to reduce the cost and the number of doses of vaccine required per immunization. A large-scale clinical effic...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/s0264-410x(00)00038-4

    authors: Markoff L

    更新日期:2000-05-26 00:00:00

  • Validity of self-reported pneumococcal vaccination status in the elderly in Spain.

    abstract::The objective of this study was to evaluate the validity of information reported by the elderly on 23-valent pneumococcal polysaccharide vaccine (23vPPV) vaccination status. A cross-sectional, observational study was carried out in patients aged >or=65 years admitted to five Spanish hospitals. Data on 23vPPV vaccinati...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.05.057

    authors: Bayas JM,Izquierdo C,Ruiz L,Sintes X,Sousa D,Celorrio JM,Varona W,Carratalà J,Nebot M,Batalla J,Sugrañes S,Manzur A,Terren A,García C,Clemente E,Rivera S,Justo I,Arévalo A,Salleras L,Domínguez A

    更新日期:2009-07-23 00:00:00

  • PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.

    abstract::The highly pathogenic avian H5N1 influenza virus has the potential to incite a global pandemic. Therefore, there is an urgent need to develop effective vaccines against these viruses. Because it is difficult to predict which strain of influenza will cause a pandemic, it is advantageous to develop vaccines that will co...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.04.074

    authors: Ichinohe T,Ainai A,Tashiro M,Sata T,Hasegawa H

    更新日期:2009-10-23 00:00:00

  • Pandemic influenza A/H1N1 vaccination uptake among health care workers in Qatar: motivators and barriers.

    abstract::Influenza A/H1N1 new vaccine helps control disease spread. Cross-sectional survey was conducted at PHC & Emergency Departments in Qatar to determine influenza A/H1N1 vaccination rate among HCWs and associated factors, 523 HCWs were enrolled. The study showed that 13.4% HCWs received vaccination. Feeling protected stro...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.08.093

    authors: Alkuwari MG,Aziz NA,Nazzal ZA,Al-Nuaimi SA

    更新日期:2011-03-03 00:00:00

  • Is freezing in the vaccine cold chain an ongoing issue? A literature review.

    abstract::Vaccine exposure to temperatures below recommended ranges in the cold chain may decrease vaccine potency of freeze-sensitive vaccines leading to a loss of vaccine investments and potentially places children at risk of contracting vaccine preventable illnesses. This literature review is an update to one previously publ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2016.09.070

    authors: Hanson CM,George AM,Sawadogo A,Schreiber B

    更新日期:2017-04-19 00:00:00

  • Development of a recombinant vaccine against aerosolized plague.

    abstract::Although few diseases have had a greater impact on human history, currently there is no vaccine available for protection against plague that is licensed by the Food and Drug Administration (FDA). DynPort Vaccine Company LLC, a CSC company (DVC), is managing the advanced development of a recombinant plague vaccine (rF1...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.01.071

    authors: Morris SR

    更新日期:2007-04-20 00:00:00

  • Risk of solid organ transplant rejection following vaccination with seasonal trivalent inactivated influenza vaccines in England: A self-controlled case-series.

    abstract:BACKGROUND:Annual seasonal influenza vaccination is recommended for transplant recipients. No formal pharmacoepidemiology study has been published on the association between solid organ transplant (SOT) rejection and vaccination with seasonal trivalent inactivated influenza vaccines (TIIVs). METHODS:The risk of SOT (l...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.05.016

    authors: Dos Santos G,Haguinet F,Cohet C,Webb D,Logie J,Ferreira GL,Rosillon D,Shinde V

    更新日期:2016-06-30 00:00:00

  • Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses.

    abstract::Various peptide-based approaches to simultaneous induction of multiple cytotoxic T lymphocyte (CTL) responses were evaluated as part of ongoing efforts to develop immunotherapeutic vaccines for use in humans. To this end, HLA (human histocompatibility leukocyte antigen)-A2-restricted epitopes from several specific vir...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(97)00264-8

    authors: Oseroff C,Sette A,Wentworth P,Celis E,Maewal A,Dahlberg C,Fikes J,Kubo RT,Chesnut RW,Grey HM,Alexander J

    更新日期:1998-05-01 00:00:00

  • Mucosal immunization with experimental feline immunodeficiency virus (FIV) vaccines induces both antibody and T cell responses but does not protect against rectal FIV challenge.

    abstract::Feline immunodeficiency virus (FIV) is a natural lentiviral pathogen of cats which can be experimentally transmitted via rectal and vaginal routes--the major routes of human immunodeficiency virus type 1 transmission in man. An important objective for lentiviral research is the development of vaccine strategies which ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(00)00131-6

    authors: Finerty S,Stokes CR,Gruffydd-Jones TJ,Hillman TJ,Reeves NA,Whiting CV,Schaaper WM,Dalsgaard K,Harbour DA

    更新日期:2000-08-01 00:00:00

  • An assessment of shedding with the oral rabies virus vaccine strain SPBN GASGAS in target and non-target species.

    abstract::A safety requirement for live vaccines is investigating possible shedding in recipients since the presence of replication competent vaccine in secretions could result in direct and indirect horizontal transmission. This is especially relevant for oral rabies vaccine baits that are deliberately distributed into the env...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.12.076

    authors: Vos A,Freuling C,Ortmann S,Kretzschmar A,Mayer D,Schliephake A,Müller T

    更新日期:2018-02-01 00:00:00

  • A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.

    abstract::West Nile virus (WNV) has caused multiple global outbreaks with increased frequency of neuroinvasive disease in recent years. Despite many years of research, there are no licensed therapeutics or vaccines available for human use. One of the major impediments of vaccine development against WNV is the potential enhancem...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.02.073

    authors: Lai H,Paul AM,Sun H,He J,Yang M,Bai F,Chen Q

    更新日期:2018-03-27 00:00:00

  • A pilot study on intradermal vaccination of Japanese rabies vaccine for pre-exposure immunization.

    abstract::Japanese rabies vaccine, a purified chick embryo cell vaccine manufactured by Kaketsuken (PCEC-K), is normally given subcutaneously; however, this requires a large amount of vaccine, and the pre-exposure vaccination regimen requires 6 months to complete. These factors often hamper appropriate vaccination. Therefore, w...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.08.068

    authors: Shiota S,Khawplod P,Ahmed K,Mifune K,Nishizono A

    更新日期:2008-11-25 00:00:00

  • Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.

    abstract::Optimal protection against malaria may require induction of high levels of protective antibody and CD8(+) and CD4(+) T cell responses. In humans, malaria DNA vaccines elicit CD8(+) cytotoxic T cells (CTL) and IFNgamma responses as measured by short-term (ex vivo) ELISPOT assays, and recombinant proteins elicit antibod...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.vaccine.2004.01.031

    authors: Epstein JE,Charoenvit Y,Kester KE,Wang R,Newcomer R,Fitzpatrick S,Richie TL,Tornieporth N,Heppner DG,Ockenhouse C,Majam V,Holland C,Abot E,Ganeshan H,Berzins M,Jones T,Freydberg CN,Ng J,Norman J,Carucci DJ,Cohen J

    更新日期:2004-04-16 00:00:00

  • Measles and rubella immunity in the population of Bhutan, 2017.

    abstract:BACKGROUND:In 2017, measles elimination was verified in Bhutan, and the country appears to have sufficiently high vaccination coverage to achieve rubella elimination. However, a measles and rubella serosurvey was conducted to find if any hidden immunity gaps existed that could threaten Bhutan's elimination status. MET...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.08.085

    authors: Wangchuk S,Nogareda F,Tshering N,Khandu L,Pelden S,Wannemuehler K,Wangdi S,Wangchuk U,Mulders M,Tamang T,Patel MK

    更新日期:2019-10-08 00:00:00

  • Rapid and high seroprotection rates achieved with a tri-antigenic Hepatitis B vaccine in healthy young adults: Results from a Phase IV study.

    abstract:BACKGROUND:Sci-B-Vac® is a tri-antigenic recombinant Hepatitis B vaccine (TAV) containing the small (s), medium (pre-S2) and large (pre-S1) hepatitis B surface (HBs) antigens. To comply with vaccine licensure, a new reference standard batch was qualified by characterizing the seroprotection rate (SPR) for anti-HBs tite...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.12.050

    authors: Atsmon J,Machluf N,Yayon-Gur V,Sabbah C,Spaans JN,Yassin-Rajkumar B,Anderson DE,Popovic V,Diaz-Mitoma F

    更新日期:2021-01-13 00:00:00

  • Structural organization of NadADelta(351-405), a recombinant MenB vaccine component, by its physico-chemical characterization at drug substance level.

    abstract::The physico-chemical characterization of NadADelta(351-405), a recombinant protein discovered by reverse vaccinology, component of a candidate vaccine against Neisseria meningitidis serotype B is presented. Analytical methods like mass spectrometry, electrophoresis, optical spectroscopy and SEC-MALLS have been applied...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.01.099

    authors: Magagnoli C,Bardotti A,De Conciliis G,Galasso R,Tomei M,Campa C,Pennatini C,Cerchioni M,Fabbri B,Giannini S,Mattioli GL,Biolchi A,D'Ascenzi S,Helling F

    更新日期:2009-03-26 00:00:00

  • Comparison of eight Lactobacillus species for delivery of surface-displayed mycobacterial antigen.

    abstract::Lactobacillus spp. comprise a large group of Gram-positive lactic acid bacteria with varying physiological, ecological and immunomodulatory properties that are widely exploited by mankind, primarily in food production and as health-promoting probiotics. Recent years have shown increased interest in using lactobacilli ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.09.012

    authors: Kuczkowska K,Øverland L,Rocha SDC,Eijsink VGH,Mathiesen G

    更新日期:2019-10-08 00:00:00

  • Development of an ex vivo human skin model for intradermal vaccination: tissue viability and Langerhans cell behaviour.

    abstract::The presence of resident Langerhans cells (LCs) in the epidermis makes the skin an attractive target for DNA vaccination. However, reliable animal models for cutaneous vaccination studies are limited. We demonstrate an ex vivo human skin model for cutaneous DNA vaccination which can potentially bridge the gap between ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.07.088

    authors: Ng KW,Pearton M,Coulman S,Anstey A,Gateley C,Morrissey A,Allender C,Birchall J

    更新日期:2009-10-09 00:00:00

  • Prothymosin alpha enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella choleraesuis.

    abstract::Previously, we showed that vaccination with the glycoprotein D (gD) gene of pseudorabies virus (PrV) delivered by Escherichia coli induced protective immune responses. In this study, we report that oral DNA vaccination with attenuated Salmonella choleraesuis carrying the PrV gD gene conferred protective immunity in mi...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(01)00130-x

    authors: Shiau AL,Chen YL,Liao CY,Huang YS,Wu CL

    更新日期:2001-07-16 00:00:00

  • Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan.

    abstract::During the endgame of global polio eradication, the universal introduction of inactivated poliovirus vaccines is urgently required to reduce the risk of vaccine-associated paralytic poliomyelitis and polio outbreaks due to wild and vaccine-derived polioviruses. In particular, the development of inactivated poliovirus ...

    journal_title:Vaccine

    pub_type: 历史文章,杂志文章,评审

    doi:10.1016/j.vaccine.2014.11.015

    authors: Shimizu H

    更新日期:2016-04-07 00:00:00

  • DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice.

    abstract::Immunization protocols based on priming with plasmid DNA and boosting with recombinants of vaccinia virus (rVV) encoding the same antigen offer great promise for the prevention and treatment of many parasitic and viral infections for which conventional vaccination has little or no effect. To overcome some of the poten...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(02)00450-4

    authors: López-Fuertes L,Pérez-Jiménez E,Vila-Coro AJ,Sack F,Moreno S,Konig SA,Junghans C,Wittig B,Timón M,Esteban M

    更新日期:2002-12-13 00:00:00

  • The benefits of redesigning Benin's vaccine supply chain.

    abstract:INTRODUCTION:New vaccine introductions have put strains on vaccine supply chains around the world. While increasing storage and transportation may be the most straightforward options, it is also important to consider what financial and operational benefits can be incurred. In 2012, suboptimal vaccine coverage and impen...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.04.090

    authors: Brown ST,Schreiber B,Cakouros BE,Wateska AR,Dicko HM,Connor DL,Jaillard P,Mvundura M,Norman BA,Levin C,Rajgopal J,Avella M,Lebrun C,Claypool E,Paul P,Lee BY

    更新日期:2014-07-07 00:00:00

  • Duration of the protective immune response after prime and booster vaccination of yearlings with a live modified cold-adapted viral vaccine against equine influenza.

    abstract::We previously created a live vaccine against equine influenza based the new reassortant cold-adapted (Ca) strain A/HK/Otar/6:2/2010. The live vaccine contains surface proteins (HA, NA) from the wild-type virus A/equine/Otar/764/2007 (Н3N8; American Lineage Florida Clade 2), and internal proteins (PB2, PB1, PA, NP, M, ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.03.095

    authors: Tabynov K,Kydyrbayev Zh,Ryskeldinova Sh,Assanzhanova N,Sansyzbay A

    更新日期:2014-05-23 00:00:00

  • Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.

    abstract::Immune responses to poorly immunogenic antigens, such as polysaccharides, can be enhanced by conjugation to carriers. Our previous studies indicate that conjugation to Vi polysaccharide of Salmonella Typhi may also enhance immunogenicity of some protein carriers. We therefore explored the possibility of generating a b...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.04.035

    authors: An SJ,Scaria PV,Chen B,Barnafo E,Muratova O,Anderson C,Lambert L,Chae MH,Yang JS,Duffy PE

    更新日期:2018-05-17 00:00:00

  • SHIV virus-like particles bind and activate human dendritic cells.

    abstract::We previously demonstrated that mucosal immunization with SHIV virus-like particles (VLPs) was able to induce strong humoral and cellular immune responses against HIV envelope protein (Env). To understand the mechanism for such enhanced immune responses, we studied the interaction between VLPs and dendritic cells (DCs...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.05.036

    authors: Zhang R,Li M,Chen C,Yao Q

    更新日期:2004-11-25 00:00:00

  • Structural perturbation of diphtheria toxoid upon adsorption to aluminium hydroxide adjuvant.

    abstract::Aluminium-containing adjuvants are often used to enhance the potency of vaccines. In the present work we studied whether adsorption of diphtheria toxoid to colloidal aluminium hydroxide induces conformational changes of the antigen. Diphtheria toxoid has a high affinity for the aluminium hydroxide particles based on a...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.09.020

    authors: Régnier M,Metz B,Tilstra W,Hendriksen C,Jiskoot W,Norde W,Kersten G

    更新日期:2012-11-06 00:00:00

  • Time and motion study to compare electronic and hybrid data collection systems during the pandemic (H1N1) 2009 influenza vaccination campaign.

    abstract::During the pandemic (H1N1) 2009 vaccination campaign, vaccine providers collected immunization data using hybrid (paper-based and electronic methods) and electronic data systems. We measured staff time in seconds spent on data collection tasks to compare system efficiencies. The sample consisted of 38 organizations ac...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.09.016

    authors: Quach S,Hamid JS,Pereira JA,Heidebrecht CL,Foisy J,Bettinger JA,Rosella L,Crowcroft NS,Deeks SL,Quan SD,Finkelstein M,Guay M,Buckeridge DL,Sikora CA,Kwong JC,Public Health Agency of Canada\/Canadian Institutes of Health Res

    更新日期:2011-02-24 00:00:00

  • An immunization program for US-bound refugees: Development, challenges, and opportunities 2012-present.

    abstract:BACKGROUND:US-bound refugees undergo required health assessments overseas to identify and treat communicable diseases of public health significance-such as pulmonary tuberculosis-before migration. Immunizations are not required, leaving refugees at risk for vaccine-preventable diseases. In response, the US Centers for ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.10.047

    authors: Mitchell T,Dalal W,Klosovsky A,Yen C,Phares C,Burkhardt M,Amin F,Froes I,Hamadeh A,Lynn SA,Quintanilla J,Doney AC,Cetron M,Weinberg M

    更新日期:2021-01-03 00:00:00